NASDAQ$VIR
Vir Biotechnology Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Vir Biotechnology reported higher Q4 2025 revenue driven by a Norgine license agreement and a narrowed net loss compared to the prior year period.
For Q4 2025, Vir reported total revenue of 64070000 primarily from license revenue, with a net loss of 42923000, reflecting reduced operating expenses year over year and a strengthened cash position of 781600000 in cash and investments.
- Total revenue increased to 64070000 from 12374000 year over year.
- License and collaboration revenue was 63760000 in Q4 2025.
- R&D expenses declined to 88349000 from 106083000 year over year.
- Net loss narrowed to 42923000 compared to 104589000 in Q4 2024.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$64.1M
Revenue by segment
Vir · $2.35M total across 2 segments · Q3 2023
- Grant revenue$6.74M+117.3%286.7%
- License & collaboration revenue-$4.39M-101.4%-186.7%
Forward guidance
Vir expects its cash, cash equivalents and investments to fund operations into the second quarter of 2028 based on current operating plans and anticipated collaboration effects.
Tailwinds
- Cash, cash equivalents and investments totaled 781600000 as of December 31, 2025.
- Company expects cash runway into the second quarter of 2028.
- Collaboration with Astellas expected to support financial position.
- Initial 64300000 payment received from Norgine in Q4 2025.
- Operating expenses declined year over year in Q4 2025.
Headwinds
- Net loss of 42923000 in Q4 2025.
- Loss from operations of 47921000 in Q4 2025.
- R&D expenses remained high at 88349000 in Q4 2025.
- Decline of approximately 29100000 in cash and investments during Q4 2025.
- Full year net loss of 437987000 in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro